JPS58105922A - 白血病治療剤 - Google Patents
白血病治療剤Info
- Publication number
- JPS58105922A JPS58105922A JP56204135A JP20413581A JPS58105922A JP S58105922 A JPS58105922 A JP S58105922A JP 56204135 A JP56204135 A JP 56204135A JP 20413581 A JP20413581 A JP 20413581A JP S58105922 A JPS58105922 A JP S58105922A
- Authority
- JP
- Japan
- Prior art keywords
- pantethine
- lysolecithin
- leukemia
- lecithin
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000032839 leukemia Diseases 0.000 title claims abstract description 31
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 claims abstract description 19
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims abstract description 19
- 229960000903 pantethine Drugs 0.000 claims abstract description 19
- 235000008975 pantethine Nutrition 0.000 claims abstract description 19
- 239000011581 pantethine Substances 0.000 claims abstract description 19
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 claims abstract description 14
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 12
- 229940067606 lecithin Drugs 0.000 claims abstract description 11
- 235000010445 lecithin Nutrition 0.000 claims abstract description 11
- 239000000787 lecithin Substances 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 3
- 238000011282 treatment Methods 0.000 claims description 9
- 210000004698 lymphocyte Anatomy 0.000 claims description 7
- 239000010836 blood and blood product Substances 0.000 claims description 3
- 229940125691 blood product Drugs 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 19
- 239000008280 blood Substances 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 11
- 241000282414 Homo sapiens Species 0.000 abstract description 7
- 102000004190 Enzymes Human genes 0.000 abstract description 4
- 108090000790 Enzymes Proteins 0.000 abstract description 4
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 abstract description 3
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 abstract description 3
- 230000002949 hemolytic effect Effects 0.000 abstract description 2
- 230000001926 lymphatic effect Effects 0.000 abstract 3
- 239000000470 constituent Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 17
- 230000007910 cell fusion Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000004820 blood count Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56204135A JPS58105922A (ja) | 1981-12-17 | 1981-12-17 | 白血病治療剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56204135A JPS58105922A (ja) | 1981-12-17 | 1981-12-17 | 白血病治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58105922A true JPS58105922A (ja) | 1983-06-24 |
| JPH0149129B2 JPH0149129B2 (https=) | 1989-10-23 |
Family
ID=16485410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56204135A Granted JPS58105922A (ja) | 1981-12-17 | 1981-12-17 | 白血病治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58105922A (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017057643A1 (ja) * | 2015-09-29 | 2017-04-06 | 国立大学法人大阪大学 | 白血球浸潤促進剤および腫瘍免疫活性化剤 |
-
1981
- 1981-12-17 JP JP56204135A patent/JPS58105922A/ja active Granted
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017057643A1 (ja) * | 2015-09-29 | 2017-04-06 | 国立大学法人大阪大学 | 白血球浸潤促進剤および腫瘍免疫活性化剤 |
| CN108136020A (zh) * | 2015-09-29 | 2018-06-08 | 国立大学法人大阪大学 | 白细胞浸润促进剂和肿瘤免疫活化剂 |
| JPWO2017057643A1 (ja) * | 2015-09-29 | 2018-08-16 | 国立大学法人大阪大学 | 白血球浸潤促進剤および腫瘍免疫活性化剤 |
| AU2016329670B2 (en) * | 2015-09-29 | 2019-12-12 | Osaka University | Leukocyte infiltration promoting agent and antitumor immunostimulatory agent |
| JP2020073572A (ja) * | 2015-09-29 | 2020-05-14 | 国立大学法人大阪大学 | 白血球浸潤促進剤および腫瘍免疫活性化剤 |
| US11033559B2 (en) | 2015-09-29 | 2021-06-15 | Osaka University | Leukocyte infiltration promoting agent and antitumor immunostimulatory agent |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0149129B2 (https=) | 1989-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Takahashi et al. | Attempt at local administration of anticancer agents in the form of fat emulsion | |
| AU723812B2 (en) | Medicinal preparation and a method of medicinal action on human organism | |
| JPH0637395B2 (ja) | ジペプタイド誘導体を含有する、筋萎縮性側索硬化症を治療するための薬剤 | |
| US5712259A (en) | NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome | |
| Roberts et al. | Diltiazem overdose: pharmacokinetics of diltiazem and its metabolites and effect of multiple dose charcoal therapy | |
| Furnas et al. | Vindesine: An Effective Agent in the Treatment of Non-Small Cell Lung | |
| US5491150A (en) | Supplementary therpeutic agents for the treatment of immunodeficiency syndrome | |
| Ayre et al. | Insulin potentiation therapy: a new concept in the management of chronic degenerative disease | |
| JPS58105922A (ja) | 白血病治療剤 | |
| Karatieieva et al. | Treatment of pyoinflammatory complications with individually selected ozone dose in patients with diabetes | |
| Zaffaroni | Systems for controlled drug delivery | |
| TSUDA et al. | Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients | |
| US4042698A (en) | Treatment of myasthenia gravis and oral medication therefor | |
| RU2200557C1 (ru) | Способ лечения гипертрофических и келоидных рубцов | |
| DeWind | Reversible manifestation of thyroiditis | |
| WO1996018410A1 (en) | Agent for treating primary liver cancer and a method of treating primary liver cancer | |
| RU2193892C2 (ru) | Способ лечения миастении | |
| RU2215527C2 (ru) | Способ купирования алкогольного абстинентного синдрома, алкогольного делирия, острого алкогольного галлюциноза | |
| EP0347927A2 (de) | Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on (Ebselen) zur Herstellung von Arzneimitteln zur Behandlung von Malaria | |
| Miser et al. | Continuous intravenous fentanyl for pain control in children and young adults with cancer | |
| RU2233664C2 (ru) | Способ лечения красного плоского лишая | |
| RU2043103C1 (ru) | Средство, уменьшающее внешнесекреторную недостаточность поджелудочной железы при хроническом панкреатите | |
| RU2142794C1 (ru) | Способ воздействия на организм лечебными средствами и лекарственное средство | |
| RU2043104C1 (ru) | Болеутоляющее средство при хроническом панкреатите | |
| Schonwald et al. | Unsuspected quinine intoxication presenting as acute deafness and mutism |